Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.

Verona Pharma PLC (NASDAQ:VRNA) shares have reached an all-time high, touching a price level of $62.09. According to ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

Vertex Pharmaceuticals continues to execute ... conservative analyst revenue projections, making the stock a STRONG BUY with a 12-month price of $550/share. As of yesterday evening, the FDA ...

This anticipated adoption, along with a projected modest market penetration, underpins the increased price target for Vertex Pharmaceuticals’ stock, contributing to Fein’s Buy rating.

Explore Sun Pharma Industries stock price history with detailed daily historical prices, including open, high, low, and volume data. Review stock chart history to analyze past trends and find the ...

The recent settlement that would see Purdue Pharma and its owners, the Sackler family, pay $7.4 billion to resolve lawsuits filed by state and local governments across the country is a welcome ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) became a popular AI stock following NVIDIA’s $ ... its Overweight rating on RXRX shares with a price target downgrade from $12 to $10.

New York Attorney General Letitia James announced Thursday a new $7.5 billion settlement with Purdue Pharmaceuticals and the Sackler Family for their role in the ongoing US opioid crisis, with the ...

NEW YORK (Reuters) - Purdue Pharma said on Friday it needs more time to build support for a new $7.4 billion settlement that could complete the company's years-long effort to resolve thousands of ...